Biogen's Anti-Tau Drug Slows Cognitive Decline, Sparks Stock Concerns
Product·3 articles across 2 outlets
Story updated Rewritten when the story materially grows; the wire is checked every 15 minutesAbout this data
Biogen's leading tau-targeting candidate has slowed cognitive decline across a suite of different clinical assessments, backing up the pharma’s decision to race the molecule into phase 3 development.
Biogen leaders took to an investor call today to defend the phase 2 readout of the company’s anti-tau Alzheimer’s disease candidate, which, despite slowing cognitive decline on par with approved medicines, sparked a significant stock slip.
Biogen
Sources
Every quote below is verbatim from the article it is attributed to.
SourceReports the news
“The study provides the clearest evidence yet that medi”
biopharma dive — Biogen data highlight promise, questions surrounding tau-targeting Alzheimer’s drugs“Biogen's leading tau-targeting candidate has slowed cognitive decline across a suite of different clinical assessments, backing up the pharma’s decision to race the molecule into phase 3 development.”
fierce biotech — <a href="/biotech/aaic-biogen-bolsters-hopes-pivotal-push-anti-tau-oligo-slows-cognitive-decline" hreflang="en">AAIC: Biogen bolsters hopes for Alzheimer's pivotal push as anti-tau oligo slows cognitive decline</a>“Biogen leaders took to an investor call today to defend the phase 2 readout of the company’s anti-tau Alzheimer’s disease candidate, which, despite slowing cognitive decline on par with approved medicines, sparked a significant stock slip.”
fierce biotech — <a href="/biotech/biogen-defends-anti-tau-drug-after-stock-slides-alzheimers-readout" hreflang="en">Biogen defends anti-tau drug after stock slides on Alzheimer’s readout</a>